Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    An exploratory study to investigate the optimal scheduling of chemotherapy in patients with operable colorectal liver metastases

    Summary
    EudraCT number
    2011-003052-40
    Trial protocol
    GB  
    Global end of trial date
    31 Jul 2015

    Results information
    Results version number
    v1(current)
    This version publication date
    06 Mar 2024
    First version publication date
    06 Mar 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    RHMCAN0763
    Additional study identifiers
    ISRCTN number
    ISRCTN32401805
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    University Hospital Southampton NHS Foundation Trust
    Sponsor organisation address
    Southampton General Hospital, Level E, Laboratory & Pathology Block, SCBR, MP 138, Southampton, United Kingdom, SO16 6YD
    Public contact
    University of Southampton Clinical Trials Unit, University of Southampton Clinical Trials Unit, 0044 2381205154, ctu@soton.ac.uk
    Scientific contact
    University of Southampton Clinical Trials Unit, University of Southampton Clinical Trials Unit, 0044 2381205154, ctu@soton.ac.uk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    01 May 2013
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    01 May 2013
    Global end of trial reached?
    Yes
    Global end of trial date
    31 Jul 2015
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    Currently some patients with colorectal cancer that has spread to the liver can be treated surgically and a significant number will effectively be cured. A prior study has shown that chemotherapy improves the survival of these patients if it is given both before and after the liver surgery. However this causes an increase in the complications of surgery. In this trial we are trying to find out if giving all the chemotherapy after surgery is possible, hence potentially avoiding this problem of complications. If this approach is feasible a larger trial will be undertaken to see if this approach is equivalent in terms of the long term survival of these patients.
    Protection of trial subjects
    Eligible participants for the trials were aged 18 years or older, with metastatic resectable liver-limited colorectal cancer, and were recruited from approved study sites. Resectability was confirmed by a liver surgeon and the protocols mandated this as completely removable disease with a microscopic margin of >1 mm achievable and an estimated preoperative margin of ≥5 mm. The number of tumors was not restricted. All studies were performed in accordance with the Declaration of Helsinki. Institutional or central ethics and research governance approval was obtained, and patients provided written informed consent.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    01 Nov 2011
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 20
    Worldwide total number of subjects
    20
    EEA total number of subjects
    20
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    20
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Eligible participants for the trials were aged 18 years or older, with metastatic resectable liver-limited colorectal cancer, and were recruited from approved study sites. Resectability was confirmed by a liver surgeon and the protocols mandated this as completely removable disease with a microscopic margin of >1 mm achievable

    Pre-assignment
    Screening details
    Participants were randomized to receive three months of preoperative and three months of postoperative treatment or six months of postoperative treatment with FOLFOX6 (5-fluorouracil plus oxaliplatin) every two weeks, FOLFIRI (5-fluorouracil plus irinotecan) every two weeks, or CAPOX every three weeks

    Period 1
    Period 1 title
    Overall study period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Surgery, than chemotherapy
    Arm description
    Surgery, than 24weeks standard chemotherapy
    Arm type
    Experimental

    Investigational medicinal product name
    mFOLFOX
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate and solvent for solution for infusion
    Routes of administration
    Infusion
    Dosage and administration details
    24 weeks

    Investigational medicinal product name
    CAPOX
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate and solvent for solution for infusion
    Routes of administration
    Infusion
    Dosage and administration details
    24 weeks

    Investigational medicinal product name
    mFOLFIRI
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate and solvent for solution for infusion
    Routes of administration
    Infusion
    Dosage and administration details
    24 weeks

    Arm title
    12weeks chemo, surgery, 12 weeks chemo
    Arm description
    12 weeks (peri-operative) standard chemotherapy, surgery, 12 weeks (post-operative) standard chemotherapy
    Arm type
    Experimental

    Investigational medicinal product name
    mFOLFOX
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate and solvent for solution for infusion
    Routes of administration
    Infusion
    Dosage and administration details
    24 weeks (12 weeks pre and post operative)

    Investigational medicinal product name
    CAPOX
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate and solvent for solution for infusion
    Routes of administration
    Infusion
    Dosage and administration details
    24 weeks (12 weeks pre and post operative)

    Number of subjects in period 1
    Surgery, than chemotherapy 12weeks chemo, surgery, 12 weeks chemo
    Started
    10
    10
    Completed
    7
    3
    Not completed
    3
    7
         didnt complete the chemotherapy
    2
    -
         progress before surgery
    -
    3
         no surgical information
    -
    1
         early termination by Sponsor, no surgery
    -
    1
         not completing the postop chemotherapy
    -
    2
         incorrect randomisation
    1
    -

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Surgery, than chemotherapy
    Reporting group description
    Surgery, than 24weeks standard chemotherapy

    Reporting group title
    12weeks chemo, surgery, 12 weeks chemo
    Reporting group description
    12 weeks (peri-operative) standard chemotherapy, surgery, 12 weeks (post-operative) standard chemotherapy

    Reporting group values
    Surgery, than chemotherapy 12weeks chemo, surgery, 12 weeks chemo Total
    Number of subjects
    10 10 20
    Age categorical
    Units: Subjects
        Age 18-69
    9 10 19
        Unknown
    1 0 1
    Age continuous
    Units: years
        median (inter-quartile range (Q1-Q3))
    65 (61 to 69) 64 (58 to 66) -
    Gender categorical
    Units: Subjects
        Female
    5 2 7
        Male
    4 8 12
        Unknown
    1 0 1

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Surgery, than chemotherapy
    Reporting group description
    Surgery, than 24weeks standard chemotherapy

    Reporting group title
    12weeks chemo, surgery, 12 weeks chemo
    Reporting group description
    12 weeks (peri-operative) standard chemotherapy, surgery, 12 weeks (post-operative) standard chemotherapy

    Primary: Recruitment feasibility

    Close Top of page
    End point title
    Recruitment feasibility [1]
    End point description
    End point type
    Primary
    End point timeframe
    32 months
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No suficient number for staistical analyses, early termination of the trial.
    End point values
    Surgery, than chemotherapy 12weeks chemo, surgery, 12 weeks chemo
    Number of subjects analysed
    10 [2]
    10 [3]
    Units: Number of patient finished the trial
    7
    3
    Notes
    [2] - Recruited patients
    [3] - Recruited patients
    No statistical analyses for this end point

    Secondary: Proportion of chemotherapy cycles

    Close Top of page
    End point title
    Proportion of chemotherapy cycles
    End point description
    End point type
    Secondary
    End point timeframe
    32 months
    End point values
    Surgery, than chemotherapy 12weeks chemo, surgery, 12 weeks chemo
    Number of subjects analysed
    9 [4]
    10
    Units: Cycles
    12
    6
    Notes
    [4] - 1 person wihdrawn because of wrong randomisation
    No statistical analyses for this end point

    Secondary: Surgical mortality and complications

    Close Top of page
    End point title
    Surgical mortality and complications
    End point description
    End point type
    Secondary
    End point timeframe
    within 30 days after the surgery
    End point values
    Surgery, than chemotherapy 12weeks chemo, surgery, 12 weeks chemo
    Number of subjects analysed
    9 [5]
    5 [6]
    Units: number of patients with complications
    2
    4
    Notes
    [5] - number of patient went through surgery
    [6] - number of patient went through surgery
    No statistical analyses for this end point

    Secondary: Treatment related toxicity

    Close Top of page
    End point title
    Treatment related toxicity
    End point description
    End point type
    Secondary
    End point timeframe
    32 months
    End point values
    Surgery, than chemotherapy 12weeks chemo, surgery, 12 weeks chemo
    Number of subjects analysed
    9 [7]
    10
    Units: patients had treatment related adverse
    8
    10
    Notes
    [7] - 1 person withdrawn because of wrong randomisation
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Timeframe for AE
    Adverse event reporting additional description
    AE additional description
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    19.0
    Reporting groups
    Reporting group title
    Arm A
    Reporting group description
    -

    Reporting group title
    Arm B
    Reporting group description
    -

    Serious adverse events
    Arm A Arm B
    Total subjects affected by serious adverse events
         subjects affected / exposed
    3 / 9 (33.33%)
    2 / 10 (20.00%)
         number of deaths (all causes)
    1
    2
         number of deaths resulting from adverse events
    0
    0
    General disorders and administration site conditions
    Fever
    Additional description: Fever
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pain
    Additional description: Pain
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Obstruction gastric
    Additional description: Obstruction gastric
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal pain
    Additional description: Abdominal pain
         subjects affected / exposed
    1 / 9 (11.11%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Hepatic pain
    Additional description: Hepatic pain
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Productive cough
    Additional description: Productive cough
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Arm A Arm B
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    8 / 9 (88.89%)
    10 / 10 (100.00%)
    Vascular disorders
    Thromboembolic event
    Additional description: Thromboembolic event
         subjects affected / exposed
    1 / 9 (11.11%)
    1 / 10 (10.00%)
         occurrences all number
    2
    1
    Hematoma
    Additional description: Hematoma
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Flushing
    Additional description: Flushing
         subjects affected / exposed
    2 / 9 (22.22%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    General disorders and administration site conditions
    Injection site reaction
    Additional description: Injection site reaction
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Edema limbs
    Additional description: Edema limbs
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Fever
    Additional description: Fever
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Fatigue
    Additional description: Fatigue
         subjects affected / exposed
    6 / 9 (66.67%)
    4 / 10 (40.00%)
         occurrences all number
    19
    9
    Pain
    Additional description: Pain
         subjects affected / exposed
    4 / 9 (44.44%)
    7 / 10 (70.00%)
         occurrences all number
    6
    11
    Respiratory, thoracic and mediastinal disorders
    Pneumothorax
    Additional description: Pneumothorax
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Laryngopharyngeal dysesthesia
    Additional description: Laryngopharyngeal dysesthesia
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Cough
    Additional description: Cough
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Epistaxis
    Additional description: Epistaxis
         subjects affected / exposed
    3 / 9 (33.33%)
    1 / 10 (10.00%)
         occurrences all number
    4
    1
    Sore throat
    Additional description: Sore throat
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    2
    Dyspnea
    Additional description: Dyspnea
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Productive cough
    Additional description: Productive cough
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Psychiatric disorders
    Anxiety
    Additional description: Anxiety
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Depression
    Additional description: Depression
         subjects affected / exposed
    1 / 9 (11.11%)
    1 / 10 (10.00%)
         occurrences all number
    2
    1
    Insomnia
    Additional description: Insomnia
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Psychiatric disorders - Other, specify
    Additional description: Psychiatric disorders - Other, specify
         subjects affected / exposed
    0 / 9 (0.00%)
    2 / 10 (20.00%)
         occurrences all number
    0
    2
    Investigations
    Neutrophil count decreased
    Additional description: Neutrophil count decreased
         subjects affected / exposed
    5 / 9 (55.56%)
    3 / 10 (30.00%)
         occurrences all number
    8
    3
    Weight loss
    Additional description: Weight loss
         subjects affected / exposed
    0 / 9 (0.00%)
    2 / 10 (20.00%)
         occurrences all number
    0
    2
    Platelet count decreased
    Additional description: Platelet count decreased
         subjects affected / exposed
    4 / 9 (44.44%)
    5 / 10 (50.00%)
         occurrences all number
    5
    6
    Hemoglobin increased
    Additional description: Hemoglobin increased
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Blood bilirubin increased
    Additional description: Blood bilirubin increased
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    White blood cell decreased
    Additional description: White blood cell decreased
         subjects affected / exposed
    3 / 9 (33.33%)
    3 / 10 (30.00%)
         occurrences all number
    3
    4
    Alanine aminotransferase increased
    Additional description: Alanine aminotransferase increased
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Injury, poisoning and procedural complications
    Fall
    Additional description: Fall
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Wound complication
    Additional description: Wound complication
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Cardiac disorders
    Palpitations
    Additional description: Palpitations
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Atrial fibrillation
    Additional description: Atrial fibrillation
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Nervous system disorders
    Peripheral sensory neuropathy
    Additional description: Peripheral sensory neuropathy
         subjects affected / exposed
    1 / 9 (11.11%)
    1 / 10 (10.00%)
         occurrences all number
    1
    4
    Dysgeusia
    Additional description: Dysgeusia
         subjects affected / exposed
    4 / 9 (44.44%)
    4 / 10 (40.00%)
         occurrences all number
    4
    7
    Nervous system disorders - Other, specify
    Additional description: Nervous system disorders - Other, specify
         subjects affected / exposed
    7 / 9 (77.78%)
    9 / 10 (90.00%)
         occurrences all number
    22
    20
    Paresthesia
    Additional description: Paresthesia
         subjects affected / exposed
    0 / 9 (0.00%)
    2 / 10 (20.00%)
         occurrences all number
    0
    2
    Headache
    Additional description: Headache
         subjects affected / exposed
    0 / 9 (0.00%)
    2 / 10 (20.00%)
         occurrences all number
    0
    2
    Neuralgia
    Additional description: Neuralgia
         subjects affected / exposed
    2 / 9 (22.22%)
    4 / 10 (40.00%)
         occurrences all number
    2
    4
    Lethargy
    Additional description: Lethargy
         subjects affected / exposed
    1 / 9 (11.11%)
    5 / 10 (50.00%)
         occurrences all number
    1
    7
    Dysesthesia
    Additional description: Dysesthesia
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Dizziness
    Additional description: Dizziness
         subjects affected / exposed
    2 / 9 (22.22%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Blood and lymphatic system disorders
    Blood and lymphatic system disorders - Other, specify
    Additional description: Blood and lymphatic system disorders - Other, specify
         subjects affected / exposed
    1 / 9 (11.11%)
    1 / 10 (10.00%)
         occurrences all number
    1
    1
    Anemia
    Additional description: Anemia
         subjects affected / exposed
    7 / 9 (77.78%)
    5 / 10 (50.00%)
         occurrences all number
    8
    6
    Febrile neutropenia
    Additional description: Febrile neutropenia
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Ear and labyrinth disorders
    Middle ear inflammation
    Additional description: Middle ear inflammation
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Tinnitus
    Additional description: Tinnitus
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Ear pain
    Additional description: Ear pain
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    3
    Eye disorders
    Eye disorders - Other, specify
    Additional description: Eye disorders - Other, specify
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Watering eyes
    Additional description: Watering eyes
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Gastrointestinal disorders
    Nausea
    Additional description: Nausea
         subjects affected / exposed
    6 / 9 (66.67%)
    7 / 10 (70.00%)
         occurrences all number
    21
    12
    Dyspepsia
    Additional description: Dyspepsia
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Vomiting
    Additional description: Vomiting
         subjects affected / exposed
    4 / 9 (44.44%)
    1 / 10 (10.00%)
         occurrences all number
    5
    1
    Abdominal pain
    Additional description: Abdominal pain
         subjects affected / exposed
    1 / 9 (11.11%)
    2 / 10 (20.00%)
         occurrences all number
    1
    4
    Gastrointestinal disorders - Other, specify
    Additional description: Gastrointestinal disorders - Other, specify
         subjects affected / exposed
    3 / 9 (33.33%)
    1 / 10 (10.00%)
         occurrences all number
    4
    1
    Flatulence
    Additional description: Flatulence
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Dry mouth
    Additional description: Dry mouth
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Abdominal distension
    Additional description: Abdominal distension
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Diarrhea
    Additional description: Diarrhea
         subjects affected / exposed
    7 / 9 (77.78%)
    7 / 10 (70.00%)
         occurrences all number
    18
    12
    Constipation
    Additional description: Constipation
         subjects affected / exposed
    4 / 9 (44.44%)
    4 / 10 (40.00%)
         occurrences all number
    6
    6
    Small intestinal obstruction
    Additional description: Small intestinal obstruction
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Anal pain
    Additional description: Anal pain
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Hemorrhoids
    Additional description: Hemorrhoids
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Mucositis oral
    Additional description: Mucositis oral
         subjects affected / exposed
    4 / 9 (44.44%)
    2 / 10 (20.00%)
         occurrences all number
    8
    6
    Skin and subcutaneous tissue disorders
    Dry skin
    Additional description: Dry skin
         subjects affected / exposed
    1 / 9 (11.11%)
    1 / 10 (10.00%)
         occurrences all number
    1
    1
    Skin and subcutaneous tissue disorders - Other, specify
    Additional description: Skin and subcutaneous tissue disorders - Other, specify
         subjects affected / exposed
    0 / 9 (0.00%)
    4 / 10 (40.00%)
         occurrences all number
    0
    4
    Alopecia
    Additional description: Alopecia
         subjects affected / exposed
    2 / 9 (22.22%)
    4 / 10 (40.00%)
         occurrences all number
    2
    4
    Rash maculo-papular
    Additional description: Rash maculo-papular
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Palmar-plantar erythrodysesthesia syndrome
    Additional description: Palmar-plantar erythrodysesthesia syndrome
         subjects affected / exposed
    2 / 9 (22.22%)
    3 / 10 (30.00%)
         occurrences all number
    2
    5
    Pruritus
    Additional description: Pruritus
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Purpura
    Additional description: Purpura
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Musculoskeletal and connective tissue disorders
    Pain in extremity
    Additional description: Pain in extremity
         subjects affected / exposed
    1 / 9 (11.11%)
    1 / 10 (10.00%)
         occurrences all number
    1
    4
    Myalgia
    Additional description: Myalgia
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Back pain
    Additional description: Back pain
         subjects affected / exposed
    1 / 9 (11.11%)
    1 / 10 (10.00%)
         occurrences all number
    1
    1
    Arthralgia
    Additional description: Arthralgia
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Arthritis
    Additional description: Arthritis
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Infections and infestations
    Mucosal infection
    Additional description: Mucosal infection
         subjects affected / exposed
    2 / 9 (22.22%)
    1 / 10 (10.00%)
         occurrences all number
    4
    1
    Upper respiratory infection
    Additional description: Upper respiratory infection
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Wound infection
    Additional description: Wound infection
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    2
    Tooth infection
    Additional description: Tooth infection
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Infections and infestations - Other, specify
    Additional description: Infections and infestations - Other, specify
         subjects affected / exposed
    1 / 9 (11.11%)
    4 / 10 (40.00%)
         occurrences all number
    2
    4
    Stoma site infection
    Additional description: Stoma site infection
         subjects affected / exposed
    3 / 9 (33.33%)
    3 / 10 (30.00%)
         occurrences all number
    4
    3
    Metabolism and nutrition disorders
    Anorexia
    Additional description: Anorexia
         subjects affected / exposed
    1 / 9 (11.11%)
    6 / 10 (60.00%)
         occurrences all number
    1
    9
    Hypokalemia
    Additional description: Hypokalemia
         subjects affected / exposed
    0 / 9 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Hyponatremia
    Additional description: Hyponatremia
         subjects affected / exposed
    1 / 9 (11.11%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Apr 29 10:12:12 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA